Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fecal microbiota transplantation + ruxolitinib + methylprednisolone
- Development stage
- Unknown
- Lead developer
- First Saint Petersburg State Medical University
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Intravenous
01
Overview
This combination therapy is being investigated as a first-line treatment for severe acute intestinal graft-versus-host disease (aGVHD) following allogeneic hematopoietic stem cell transplantation. The regimen integrates three distinct therapeutic modalities: fecal microbiota transplantation (FMT) to restore gut microbial diversity and intestinal barrier integrity; ruxolitinib, a small molecule Janus kinase (JAK) 1/2 inhibitor that blocks pro-inflammatory cytokine signaling; and methylprednisolone, a standard-of-care glucocorticoid for broad immunosuppression. This multi-targeted approach aims to improve response rates in patients who typically show poor outcomes with steroid monotherapy. The clinical evaluation is led by St. Petersburg State Pavlov Medical University.
- Other names
- FMT + ruxolitinib + steroidsallogeneic fecal microbiota + ruxolitinib + methylprednisolone
02
Targets
Beyond the preview
Go deeper on fecal microbiota transplantation + ruxolitinib + methylprednisolone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fecal microbiota transplantation + ruxolitinib + methylprednisolone.